Latest news
KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)
Read more
The power of precision.
For every cancer patient.
Today.
Press releases & news
-
KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)
Read more -
BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN 2CUREX AB (PUBL)
Read more -
2cureX AB Announces the Appointment of Dan Honeywell as CEO, Ushering in a New Era of commercial expansion of breakthrough precision oncology products
Read more -
KALLELSE TILL EXTRA BOLAGSSTÄMMA I 2CUREX AB
Read more
Latest report
Share Information
See our latest share informationCalendar & upcoming events
-
2cureX Webcast and Q&A – 2cureX’s Executive Management and Board of Directors are pleased to invite you to a webcast on 24 September 2024 at 20:00 CET.
Watch recording of this event -
-
2cureX Webcast – Join us at 20:00 CET on October 26 for the latest news from the third quarter of 2023 and a Q&A with the 2cureX Management.
Watch webcast -
Commentary on Q2 2023 report – Infront Direkt Studios will host an interview with CEO Fernando Andreu regarding the results presented in the Q2 2023 report.
Watch webcast
STAY UPDATED WITH OUR NEWS AND PRESS RELEASES
Get notified by mail when news or press releases are published on our website.
CEO Blog
In this latest blog, Fernando Andreu talks about the exciting expansion of the IndiTreat® product family to include a functional drug sensitivity test for pancreatic cancer in the near future.
Subscribe to our newsletter above.
More
Information for Oncologists and Pathologists
Know more when it matters most:
With our IndiTreat® tests you can finally obtain personalised information, even on the classic compounds for the main chemotherapy backbone for your stage IV mCRC patients.
Information for Patients
You’ve been diagnosed with colorectal cancer, and it is in stage IV. There are rational treatment choices to be made. Which therapy is more likely to impact the tumor? Ask your doctor about IndiTreat®.
More